Implications of asymptomatic carriers for infectious disease transmission and control

Royal Society Open Science

Volumn 5, Issue 2, 2018, Pages

  Chisholm, Rebecca H ^a   Campbell, Patricia T ^c,d   Wu, Yue ^e   Tong, Steven Y C ^d,f   McVernon, Jodie ^a,c,d   Geard, Nicholas ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Asymptomatic infection; Epidemiology; Infectious disease control; Mathematical modelling; Pathogen carriage

Indexed keywords

EID: 85043498117     PISSN: None     EISSN: 20545703     Source Type: Journal    
DOI: 10.1098/rsos.172341     Document Type: Article

References (42)

1. Furuya-Kanamori L, Cox M, Milinovich GJ, Magalhaes RJS, Mackay IM, Yakob L. 2016 Heterogeneous and dynamic prevalence of asymptomatic influenza virus infections. Emerg. Infect. Dis. 22, 1052. (doi:10.3201/eid2206.151080)
2. Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. 2005 Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region, Northeastern Gabon, 1997. J. Infect. Dis. 191, 964–968. (doi:10.1086/427994)
3. Dean NE, Halloran ME, Yang Y, Longini IM. 2016 Transmissibility and pathogenicity of ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin. Infect. Dis. 62, 1277–1286. (doi:10.1093/cid/ciw114)
4. Caugant DA, Maiden MC. 2009 Meningococcal carriage and disease—population biology and evolution. Vaccine 27, B64–B70. (doi:10.1016/j.vaccine.2009.04.061)
5. DeMuri GP, Wald ER. 2014 The group A streptococcal carrier state reviewed: still an enigma. J. Pediatric. Infect. Dis. Soc. 3, 336–342. (doi:10.1093/jpids/piu030)
6. van Belkum A. 2016 Hidden Staphylococcus aureus carriage: Overrated or underappreciated? MBio 7, e00079–16. (doi:10.1128/mBio.00079-16)
7. Shenoy ES, Paras ML, Noubary F, Walensky RP, Hooper DC. 2014 Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect. Dis. 14, 177. (doi:10.1186/1471-2334-14-177)
8. Gerding DN, Muto CA, Owens Jr RC. 2008 Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 46, S43–549. (doi:10.1086/521861)
9. Bellan SE, Pulliam J, Dushoff J, Meyers LA. 2014 Ebola control: effect of asymptomatic infection and acquired immunity. Lancet 384, 1499–1500. (doi:10.1016/S0140-6736(14)61839-0)
10. Arreaza L, de La Fuente L, Vázquez J. 2000 Antibiotic susceptibility patterns of Neisseria meningitidis isolates from patients and asymptomatic carriers. Antimicrob. Agents Ch. 44, 1705–1707. (doi:10.1128/AAC.44.6.1705-1707.2000)
11. Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, O’Meara W, Price RN, Riley EM. 2016 ‘Asymptomatic’ malaria: a chronic and debilitating infection that should be treated. PLoS Med. 13, e1001942. (doi:10.1371/journal.pmed.1001942)
12. Robinson M, Stilianakis NI. 2013 A model for the emergence of drug resistance in the presence of asymptomatic infections. Math. Biosci. 243, 163–177. (doi:10.1016/j.mbs.2013.03.003)
13. Stilianakis NI, Perelson AS, Hayden FG. 1998 Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J. Infect. Dis. 177, 863–873. (doi:10.1086/515246)
14. Wang X, Panchanathan S, Chowell G. 2013 A data-driven mathematical model of CA-MRSA transmission among age groups: evaluating the effect of control interventions. PLoS Comput. Biol. 9, e1003328. (doi:10.1371/journal.pcbi.1003328)
15. Macal CM et al. 2014 Modeling the transmission of community-associated methicillin-resistant Staphylococcus aureus: a dynamic agent-based simulation. J. Transl. Med. 12, 124. (doi:10.1186/1479-5876-12-124)
16. Hogea C, van Effelterre T, Acosta CJ. 2014 A basic dynamic transmission model of Staphylococcus aureus in the US population. Epidemiol. Infect. 142, 468–478. (doi:10.1017/S0950268813001106)
17. Hogea C, Van Effelterre T, Cassidy A. 2014 A model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures? BMC Infect. Dis. 14, 291. (doi:10.1186/1471-2334-14-291)
18. Lee BY, Bailey RR, Smith KJ, Muder RR, Strotmeyer ES, Lewis GJ, Ufberg PJ, Song Y, Harrison LH. 2010 Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect. Control Hosp. Epidemiol. 31, 598–606. (doi:10.1086/652524)
19. Zadoks R, Allore H, Hagenaars T, Barkema H, Schukken Y. 2002 A mathematical model of Staphylococcus aureus control in dairy herds. Epidemiol. Infect. 129, 397–416. (doi:10.1017/S0950268802007483)
20. Chamchod F, Ruan S. 2012 Modeling methicillin-resistant Staphylococcus aureus in hospitals: transmission dynamics, antibiotic usage and its history. Theor. Biol. Med. Model. 9, 25. (doi:10.1186/1742-4682-9-25)
21. Deeny SR, Worby CJ, Tosas Auguet O, Cooper BS, Edgeworth J, Cookson B, Robotham JV. 2015 Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA. J. Antimicrob. Chemother. 70, 3366–3378. (doi:10.1093/jac/dkv249)
22. Webb GF, Horn MA, D’Agata EMC, Moellering Jr RC, Ruan S. 2010 Competition of hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus strains in hospitals. J. Biol. Dyn. 4, 115–129. (doi:10.1080/175137509030 26411)
23. Chapman K, Wilson D, Gorton R. 2013 Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England. Epidemiol. Infect. 141, 344–352. (doi:10.1017/S0950268812000763)
24. Clancy D, Mendy ST. 2010 The effect of waning immunity on long-term behaviour of stochastic models for the spread of infection. J. Math. Biol. 61, 527–544. (doi:10.1007/s00285-009-0313-4)
25. Vargas-De-León C. 2011 On the global stability of SIS, SIR and SIRS epidemic models with standard incidence. Chaos Solitons Fractals 44, 1106–1110. (doi:10.1016/j.chaos.2011.09.002)
26. van den Driessche P, Watmough J. 2002 Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 180, 29–48. (doi:10.1016/S0025-5564(02)00108-6)
27. Hethcote HW. 1989 Three basic epidemiological models. In Applied Mathematical Ecology (eds SA Levin, TG Hallam, LJ Gross). Biomathematics, vol. 18, pp. 119–144. Berlin, Germany: Springer.
28. Kalajdzievska D, Li MY. 2011 Modeling the effects of carriers on transmission dynamics of infectious diseases. Math. Biosci. Eng. 8, 711–722. (doi:10.3934/mbe.2011.8.711)
29. Ejima K, Aihara K, Nishiura H. 2013 The impact of model building on the transmission dynamics under vaccination: observable (symptom-based) versus unobservable (contagiousness-dependent) approaches. PLoS ONE 8, e62062. (doi:10.1371/journal.pone.0062062)
30. Hsu S-B, Hsieh Y-H. 2008 On the role of asymptomatic infection in transmission dynamics of infectious diseases. Bull. Math. Biol. 70, 134–155. (doi:10.1007/s11538-007-9245-6)
31. R0. J. R. Soc. Interface 4, 949–961. (doi:10.1098/rsif. 2007.1031)
32. Buonomo B, Lacitignola D. 2012 Forces of infection allowing for backward bifurcation in an epidemic model with vaccination and treatment. Acta Appl. Math. 122, 283–293. (doi:10.1007/s10440-012-9743-x)
33. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW. 2014 Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J. Infect. Dis. 210, 1001–1011. (doi:10.1093/infdis/jiu213)
34. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW. 2006 Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193, 1487–1494. (doi:10.1086/503805)
35. Bogaert D, de Groot R, Hermans P. 2004 Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4, 144–154. (doi:10.1016/S1473-3099(04)00 938-7)
36. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. 2011 Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11, 760–768. (doi:10.1016/S1473-3099(11)70090-1)
37. Houseman C, Hughes GJ, Chapman KE, Wilson D, Gorton R. 2017 Increased invasive pneumococcal disease, North East England, UK. Emerg. Infect. Dis. 23, 122–126. (doi:10.3201/eid2301.160897)
38. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005 The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5, 685–694. (doi:10.1016/S1473-3099(05)70267-X)
39. Marimuthu K, Pittet D, Harbarth S. 2014 The effect of improved hand hygiene on nosocomial MRSA control. Antimicrob. Resist. Infect. Control 3, 34. (doi:10.1186/2047-2994-3-34)
40. David MZ, Daum RS. 2010 Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23, 616–687. (doi:10.1128/CMR.00081-09)
41. Global tuberculosis report 2017. 2017 Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO.
42. Bowen A, Harris T, Holt D, Giffard P, Carapetis J, Campbell P, McVernon J, Tong S. 2016 Whole genome sequencing reveals extensive community-level transmission of group A Streptococcus in remote communities. Epidemiol. Infect. 144, 1991–1998. (doi:10.1017/S095026881 500326X)